Sign In
Buy NVO
$47.41
-0.0100 (-0.0211%)
At Close: Jun 24, 2026
Wegovy maker Novo Nordisk sues nine spas, clinics and pharmacies over copycat drugs
10:03am, Thursday, 30'th May 2024
Novo Nordisk said on Thursday it had sued nine more medical spas, wellness clinics and pharmacies in the U.S. for selling products claiming to contain semaglutide, the key ingredient in its popular we
Catalent stockholders approve deal with Novo Holdings
09:21am, Wednesday, 29'th May 2024
Catalent said on Wednesday its stockholders have voted to approve its deal with Novo Holdings, the parent company of Novo Nordisk.
Novo Nordisk blames middlemen in U.S. healthcare system for high prices of weight loss drugs Wegovy and Ozempic
11:46am, Tuesday, 28'th May 2024
Novo Nordisk has blamed middlemen in the U.S. healthcare system for the high prices of its top-selling weight-loss drugs Wegovy and Ozempic, following the launch of an investigation into the drugs led
Is Trending Stock Novo Nordisk A/S (NVO) a Buy Now?
10:05am, Tuesday, 28'th May 2024
Zacks.com users have recently been watching Novo Nordisk (NVO) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Novo blames US health system after criticism over Wegovy price, Bloomberg reports
07:59am, Tuesday, 28'th May 2024
Novo Nordisk said it retains about 60% of the list price of its popular diabetes and obesity drugs - Ozempic and Wegovy - after rebates and fees paid to middlemen in the United States, according to a
7 Biotech Stocks to Put on Your Breakthrough Radar
12:32pm, Monday, 27'th May 2024
For those seeking to decipher best speculative opportunities in the market, biotech stocks with breakthrough potential may offer plenty of firepower. Let's get some of the bad stuff out of the way fir
Novo Nordisk A/S - share repurchase programme
08:49am, Monday, 27'th May 2024
Bagsværd, Denmark, 27 May 2024 – On 6 May 2024, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of
Novo Nordisk: Considerable Growth Beyond Ozempic
10:40pm, Sunday, 26'th May 2024
Novo Nordisk is a Danish pharmaceutical company specializing in treatments for diabetes, obesity, and rare diseases. The company's main source of income comes from diabetes treatments, including insul
Where Will Novo Nordisk Be in 10 Years?
09:15am, Saturday, 25'th May 2024
Novo Nordisk has been a dominant stock lately thanks to Ozempic, and to a lesser extent, Wegovy. The weight-loss market will, however, get a lot more crowded over the next 10 years.
Wegovy users have less kidney-related health problems, analysis of Novo study finds
07:27am, Saturday, 25'th May 2024
Novo Nordisk's Wegovy obesity drug reduced adverse kidney-related events by 22% in overweight and obese people in a large study, according to a new analysis the Danish drugmaker published on Saturday.
5 Dividend Aristocrats To Sell Before It's Too Late
07:00am, Saturday, 25'th May 2024
Buying stocks at record highs doesn't necessarily mean lower returns, and can actually lead to higher returns in the short term. Valuations matter, but the metric used to evaluate them is important. C
3 High-Flying Stocks That Could Soar Even More
06:47am, Saturday, 25'th May 2024
Eli Lilly is just getting started with its powerful obesity drug and a loaded pipeline. It's not too late to invest in scorching-hot Novo Nordisk.
US FDA panel votes against use of Novo Nordisk's weekly insulin in type 1 diabetes patients
04:40pm, Friday, 24'th May 2024
A panel of independent experts to the U.S. health regulator on Friday voted against the use of Novo Nordisk's weekly insulin in patients with type 1 diabetes due to risks of low blood sugar.
Ozempic cuts kidney-disease risks, research finds
09:27am, Friday, 24'th May 2024
Novo Nordisk's diabetes drug Ozempic reduces the risk of kidney failure and death in patients who have both Type 2 diabetes and chronic kidney disease, according to new research published Friday in th
Novo Nordisk's Ozempic slows diabetic kidney disease progression in trial
06:33am, Friday, 24'th May 2024
Novo Nordisk's Ozempic slowed the worsening of kidney dysfunction in patients with type 2 diabetes and lowered the risk of kidney failure, heart problems, stroke and death, according to detailed resul
